Allezoe Medical Holdings Inc (ALZM) Shares Open Lower On High volume

Allezoe Medical Holdings, Inc. (OTCBB: ALZM) today announced the launch of its new wholly-owned subsidiary, SureScreen Medical, Inc. Allezoe Medical Holdings, Inc. (ALZM), a holding company focused on acquiring the most high-quality and in demand medical products, solutions and services, is speeding with the recent announcement and also the “see and treat” technology for on-the-spot diagnosis of Human Papillomavirus (HPV).

SureScreen Medical will be accountable for carrying out Allezoe’s HPV diagnostic technology through the appropriate trials and federal clearances and coordination of powerful market strategy at a later stage. Allezoe CEO Michael Gelmon says, “Many technologies do not see the light of day because companies fail to go through the proper processes and channels to commercialize what they have in hand.

We are committed to a thorough process that can be rewarding for the healthcare field and our shareholders.” With the growing health concern of HPV, a subsidiary is apposite to devise the process. While SureScreen Medical will initially focus on launching the diagnostic treatment for women on a global scale, the company has already honed in on the applications of the technology for the men and veterinary fields.

Once the regulatory process is through, Allezoe’s non-invasive technology to the $18B diagnosis and treatment market (10%) around the world would be available. The Company hopes to see the market expanding to its fullest as patients and their providers settle toward the efficient, affordable technology.

Shares of ALZM fell 2.86% to $0.272 on over 82K shares.


The assembled information distributed by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented herein. will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.

Our Research Report on alzm is now available. Don´t Trade alzm until you Read our FREE FULL REPORT. Click Here